Haemonetics Corporation
NYSE:HAEMedical - Instruments & Supplies
+$0.84 today
- Market cap
- $5.59B
- Beta
- 0.54
- P/E (TTM)
- 34.9
- EPS (TTM)
- $2.11
Volume 0.48M
Average 0.88M
HAE Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Haemonetics CorporationNYSE: HAE
Cash & Equivalents · Q1 FY2027 · quarter ended Jun 2026
Cash & equivalents falls 23.7% from a year ago
Cash & equivalents stood at $223.38M at the end of Q1 FY2027, down 23.7% from a year earlier and down 9.0% from the prior quarter. Over 3 fiscal years it compounded at -4.8% a year.
Context
- Cash & equivalents amounted to 9.4% of total assets at the end of Q1 FY2027, down 2.5 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -23.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2026
- 245.44M USD
- Year-over-year change
- -20.0%
- 4-year CAGR
- -1.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-28 | 245.44M | -20.0% |
| FY2025 | 2025-03-29 | 306.76M | +71.6% |
| FY2024 | 2024-03-31 | 178.8M | -37.1% |
| FY2023 | 2023-03-31 | 284.47M | +9.6% |
| FY2022 | 2022-03-31 | 259.5M | — |
Cash & Equivalents vs competitors
How HAE compares with its peers on the latest reported figures
- HAE's Jun 2026 cash & equivalents of $223.38M is the 4th highest of the 10 companies compared; the peer median is $190M.
- Its year-over-year change of -23.7% is the 9th highest of 10, against a peer median of +5.7%.
- Cash & equivalents amounts to 9.4% of total assets for HAE, versus a peer median of 4.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.83B | +5.7% | +32.9% | 7.4% | |
| Mar 2026 | $755.86M | +30.2% | +33.5% | 65.9% | |
| Jun 2026 | $292.67M | +2.2% | +11.1% | 37.9% | |
| Jun 2026 | $223.38M | -23.7% | -4.8% | 9.4% | |
| Jun 2026 | $219.83M | -22.1% | +8.2% | 15.9% | |
| Mar 2026 | $190M | -52.3% | -3.7% | 3.6% | |
| Mar 2026 | $140.4M | +10.5% | -16.6% | 2.5% | |
CONConcentra Group Holdings Parent, Inc. | Sep 2026 | $85.82M | +71.8% | +28.5% | 2.8% |
| Mar 2026 | $26.85M | +6.0% | +13.9% | 4.3% | |
| Jul 2026 | $21.38M | -7.6% | -10.9% | 0.6% | |
| Peer median (excluding HAE) | $190M | +5.7% | +11.1% | 4.3% | |
Competitors are the stored peer set for HAE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 259.5M | 284.47M | 178.8M | 306.76M | 245.44M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 159.38M | 179.14M | 206.56M | 202.66M | 216.86M |
| Inventory | 293.03M | 259.38M | 317.2M | 365.14M | 306.37M |
| Other Current Assets | 0 | 46.74M | 66.34M | 60.41M | 66.21M |
| Total Current Assets | 756.03M | 769.72M | 768.9M | 934.98M | 834.88M |
| Property, Plant & Equipment (Net) | 258.48M | 310.89M | 366.63M | 284.05M | 305.76M |
| Goodwill | 467.29M | 466.23M | 565.08M | 604.27M | 656.37M |
| Intangible Assets | 310.26M | 275.77M | 406.12M | 455.74M | 447.66M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 4.47M | 5.24M | 7.74M | 7.8M | 9.52M |
| Other Non-current Assets | 63.21M | 106.98M | 81.12M | 164.11M | 141.74M |
| Total Non-current Assets | 1.1B | 1.17B | 1.43B | 1.52B | 1.56B |
| Total Assets | 1.86B | 1.93B | 2.2B | 2.45B | 2.4B |
| Account Payables | 58.37M | 63.93M | 73.36M | 67M | 51.06M |
| Short-term Debt | 214.15M | 11.78M | 10.23M | 303.56M | 5.02M |
| Tax Payables | 13.91M | 0 | 0 | 0 | 0 |
| Deferred Revenue | 26.81M | 30.21M | 31.24M | 43.35M | 42.31M |
| Other Current Liabilities | 87.2M | 81.42M | 104.85M | 104.79M | 116.03M |
| Total Current Liabilities | 442.27M | 251.82M | 300.38M | 578.11M | 282.6M |
| Long-term Debt | 559.44M | 754.1M | 797.56M | 921.23M | 1.22B |
| Deferred Tax Liabilities | 28.73M | 36.2M | 62.64M | 62.58M | 38.05M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 79.88M | 74.72M | 75.04M | 68.19M | 59.39M |
| Total Non-current Liabilities | 668.04M | 865.01M | 935.25M | 1.05B | 1.32B |
| Total Liabilities | 1.11B | 1.12B | 1.24B | 1.63B | 1.6B |
| Common Stock | 511K | 504K | 508K | 482K | 453K |
| Retained Earnings | 202.39M | 253.17M | 360.46M | 352.17M | 279.34M |
| Accumulated OCI | (25.95M) | (30.38M) | (35.63M) | (55.08M) | (37.61M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 749.42M | 818M | 959.96M | 820.84M | 796.32M |
| Total Debt | 780.79M | 765.89M | 807.79M | 1.22B | 1.22B |
| Net Debt | 521.29M | 481.42M | 628.99M | 918.03M | 979.14M |
Haemonetics Corporation
NYSE:HAE
Intrinsic Alpha fair value
Locked
Current Price
$122.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.